Chondrotoxicity and toxicokinetics of novel quinolone antibacterial agents DC-159a and DX-619 in juvenile rats

被引:14
|
作者
Goto, Koichi [1 ]
Yabe, Koichi [1 ]
Suzuki, Takami [1 ]
Jindo, Toshimasa [1 ]
Sanbuissho, Atsushi [1 ]
机构
[1] DAIICHI SANKYO CO LTD, Med Safety Res Labs, Edogawa Ku, Tokyo 1348630, Japan
关键词
DC-159a; DX-619; Ofloxacin; Chondrotoxicity; Toxicokinetics; Real-time RT-PCR; ARTICULAR-CARTILAGE; INDUCED ARTHROPATHY; MATRIX METALLOPROTEINASES; IN-VITRO; OFLOXACIN; FLUOROQUINOLONE; CHONDROCYTES; PLASMA; TWEAK; VIVO;
D O I
10.1016/j.tox.2010.07.017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quinolone antibacterial agents are extensively utilized in antimicrobial chemotherapy. However, they have been reported to induce arthropathy in juvenile animals, and the mechanism has not been clarified. Recently, we have demonstrated that Duspl, Tnfrsfl 2a, Ptgs2, Fos, Mtl a, Plaur, Mmp3, Sstrl and Has2 genes change in the articular cartilage of juvenile rats with a single oral administration of ofloxacin (OFLX), suggesting that these genes are involved in the induction of OFLX-induced chondrotoxicity. In the present study, to compare the chondrotoxic potential between new synthesized quinolones DC-159a and DX-619, and OFLX, they were orally administered by gavage at a dose level of 300 or 900 mg/kg/day to male juvenile Sprague-Dawley (SD) rats, 3 weeks of age, for 7 days. Then the distal humerus and femur were subjected to microscopic examination. Moreover, concentrations of these quinolones in the femoral articular cartilage were measured in male juvenile SD rats following a single oral administration at 100, 300 or 900 mg/kg. Furthermore, gene expression of Duspl, Tnfrsfl 2a, Ptgs2, Fos, Mtl a, Plaur, Mmp3, Sstrl and Has2 was investigated in the articular cartilage of the distal femur in male juvenile SD rats treated with 900 mg/kg of DC-159a or DX-619 by quantitative real-time reverse transcriptionpolymerase chain reaction (qRT-PCR) analysis. In a microscopic examination, no changes in the articular cartilage were observed in any animal administered DC-159a or DX-619. On the contrary, cavity formation and chondrocyte cluster in the cartilage of distal humerus and femur were noted in animals receiving OFLX at 300 mg/kg/day or more. In toxicokinetic analysis, the maximum concentration (C(max)) value in the articular cartilage (cartilage Cmax) of DC-159a or DX-619 at 900 mg/kg was lower than that of OFLX at 300 mg/kg. However, the area under the cartilage concentration-time curve (cartilage AUC)(0-24) h value of DC-159a or DX-619 at 900 mg/kg was higher than that of OFLX at 300 mg/kg. In qRT-PCR analysis, up-regulated Duspl, Fos and Mtl a, and down-regulated Sstrl and Has2 genes were seen in the femoral articular cartilage of rats given DX-619 or DC-159a at 900 mg/kg. However, Tnfrsfl 2a, Ptgs2, Plaur and Mmp3 genes, which were up-regulated in the distal femoral articular cartilage exposed to OFLX, did not increase or slightly increased. In conclusion, the penetration of DC-159a or DX-619 into the cartilage was low compared with that of OFLX, and no obvious changes in Tnfrsfl 2a, Ptgs2, Plaur and Mmp3 genes were observed in the articular cartilage of juvenile rats treated with DC-159a or DX-619, which was likely to be responsible for non-chondrotoxic potentials of DC-159a and DX-619. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:122 / 127
页数:6
相关论文
共 17 条
  • [1] In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone
    Fujikawa, K
    Chiba, M
    Tanaka, M
    Sato, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 3040 - 3045
  • [2] In vitro antibacterial activity of DX-619, a novel Des-F (6)-quinolone against clinical isolates in China
    Xiao, Yonghong
    Li, Yun
    Liu, Jian
    Zhong, Wei
    Yang, Weiwei
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (06) : 632 - 642
  • [3] In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone (Vol 49, pg 3040, 2005)
    Fujikawa, K
    Chiba, M
    Tanaka, M
    Sato, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) : 3988 - 3988
  • [4] Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents
    Bogdanovich, T
    Esel, D
    Kelly, LM
    Bozdogan, B
    Credito, K
    Lin, GR
    Smith, K
    Ednie, LM
    Hoellman, DB
    Appelbaum, PC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) : 3325 - 3333
  • [5] In Vitro Antibacterial Activity of DX-619, A Novel Des-Fluoro(6)-Quinolone, Against Multidrug-resistant Gram-positive Bacteria
    Fujikawa, Katsuko
    Ishida, Hiroko
    Chiba, Megumi
    Tanaka, Mayumi
    Sato, Kenichi
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S79 - S79
  • [6] Therapeutic Efficacy of Parenteral or Oral DX-619, A Novel Des-Fluoro(6)-Quinolone, in MRSA Infection Models
    Namba, Kenji
    Kurosaka, Yuichi
    Nishida, Saori
    Sawada, Yukie
    Sato, Kenichi
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 26 : S81 - S81
  • [7] In vitro activity of DX-619, a novel des-fluoro(6) quinolone, against a panel of Streptococcus pneumoniae mutants with characterized resistance mechanisms
    Wickman, PA
    Moland, ES
    Black, JA
    Thomson, KS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) : 796 - 798
  • [8] Toxic effects of quinolone antibacterial agents on the musculoskeletal system in juvenile rats
    Kashida, Y
    Kato, M
    TOXICOLOGIC PATHOLOGY, 1997, 25 (06) : 635 - 643
  • [9] Modeling and simulation to predict optimal doses of a novel fluro-quinolone, DC-159a in healthy subjects and special population
    Zahir, Hamim
    Rohatagi, Shashank
    Falcoz, Christine
    Kshirsaga, Smita
    Khariton, Tatiana
    Mouksassi, Samer
    Kuwabara-Wagg, Jon
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1109 - 1109
  • [10] Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619
    Watanabe, Shinya
    Ito, Teruyo
    Hiramatsu, Keiichi
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (06) : 1384 - 1387